Neo Ivy Capital Management Alkermes Plc. Transaction History

Neo Ivy Capital Management

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 29, 2023	BUY	$27.17 - $31.97 $546,986 - $643,620	20,132 New	20,132 $564,000
Q4 2022 Mar 24, 2023	BUY	$21.94 - $26.24 $81,221 - $97,140	3,702 New	3,702 $96,000
Q2 2022 Aug 16, 2022	BUY	$26.4 - $30.54 $23,971 - $27,730	908 New	908 $27,000
Q1 2022 May 16, 2022	SELL	$23.07 - $27.99 $5,975 - $7,249	-259 Closed	0 $0
Q4 2021 Feb 15, 2022	BUY	$21.47 - $32.08 $5,560 - $8,308	259 New	259 $6,000
Q2 2021 Aug 16, 2021	SELL	$18.78 - $25.15 $29,559 - $39,586	-1,574 Closed	0 $0
Q1 2021 Oct 07, 2021	BUY	$18.21 - $23.2 $2,403 - $3,062	132 Added 9.15%	1,574 $29,000
Q4 2020 Feb 16, 2021	BUY	$15.39 - $22.1 $22,192 - $31,868	1,442 New	1,442 $29,000

363

181M

175K

96.6K

Ticker ALKS
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 164,254,000
Market Cap $4.72B
Description
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ...

Get notified when there are updates to the investment portfolio of Neo Ivy Capital Management, based on Form 13F filings with the SEC.

Stay updated on Neo Ivy Capital Management with notifications on news.